Immunotherapy: Taking Aim at Solid Cancers

BPI Contributor

June 28, 2019

1 Min Read

17-6-Ph-Immunotherapy-230x300.jpgAs cell and gene therapies arrive on the market, all eyes have focused on autologous chimeric antigen receptor (CAR) T – cell therapies. At the 2019 Phacilitate Leaders World and Stem Cell Summit in Miami, FL, delegates looked at where the biopharmaceutical industry is going in the cellular immunotherapy space. Whether for off-the-shelf CAR T-cell products, personalized cancer vaccines, or modified natural killer (NK) cells derived from human induced pluripotent stem cells (iPSCs) — cell and gene therapy development is driving research and development engines toward one goal: destroying solid tumor cancers.

This eBook details the presentations and conversations focusing on these topics and much more…

You May Also Like